Clinical Assessments Sample Clauses

Clinical Assessments. The center created monitoring tools to evaluate the accuracy and thoroughness of clinical assessments. The tools identify areas of strength that can be generalized to other functions, as well as identify areas for improvement. They are also used to develop and monitor corrective action plans to achieve desired outcomes. Timeliness of assessments is much improved and appropriate areas of need are better addressed by IDTs, which leads to better outcomes for individuals. At least one annual medical assessment for each primary care physician is reviewed by leadership every month to monitor for completeness, timeliness, and quality of content. After review, leadership notes suggested changes and meets with the physician to discuss the findings.
Sample 1
AutoNDA by SimpleDocs
Clinical Assessments. All new participants underwent a clinical assessment by a psychiatrist (Xx Xxxxxx Xxxxxx, Xx Xxxxxx Xxxxxxxxx or Xx Xxxxxxx Xxxx). A structured diagnostic interview using the Schedule for Affective Disorders and Schizophrenia-Lifetime version (SADS- L) (Endicott and Xxxxxxx 1978) was completed to enable a DSM-IV diagnosis to be reached. Medical records were consulted where available if any uncertainty remained concerning diagnosis. The Positive and Negative Syndrome Scale (PANSS) (Xxx et al. 1987) was also completed by the clinician during the assessment.
Sample 1
Clinical Assessments. Complete Physical Exam (Steps 1 or 2) A complete physical exam will be performed at screening and at discontinuation only and will include axillary or oral temperature (centigrade), pulse, height (cm), weight (kg), blood pressure, and examination of the following body compartments: HEENT (head, eyes, ears, nose, and throat), neck, chest, heart, abdomen, extremities, skin, and neurologic. All information should be recorded on the CRF. Targeted Physical Exam (Steps 1 or 2 and beginning at week 12 in Step 3) A targeted physical examination will be performed at each study visit, beginning at entry. Each examination will include documentation of xxxxx xxxxx (axillary or oral temperature [centigrade], blood pressure, weight [kg], and respiratory rate) and will be driven by any signs or symptoms previously identified that the participant has experienced since the last visit. All information should be recorded on the CRF. Signs and Symptoms At entry, all signs/symptoms, regardless of grade, that occurred within 30 days prior to entry must be recorded on the CRF. After entry, on Steps 1 and 2, all signs, symptoms, HIV-related and AIDS-defining events, deaths and toxicities must be documented. Any signs or symptoms that led to a change in treatment, regardless of grade, must be recorded on the CRF. All WHO Stage 3 or 4 signs or symptoms must be reported on the CRFs. All rashes, regardless of grade, must be recorded on the CRF. All other signs and symptoms Grade ≥3 must be recorded on the CRF. In Step 3, only signs or symptoms that led to a change in treatment or are associated with a reportable diagnosis, regardless of grade, must be recorded on the CRF. Sites should refer to The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004, which is available on the RCC website: xxxx://xxx.xxxx-xxx-xxxx.xxx/. Diagnoses: Step 1, Step 2, and Step 3 After entry, only diagnoses identified by the ACTG Criteria for Clinical Events and Other Diseases (xxxx://xxx.xxxxx.xxx/ACTG/appendices/appendices.html) as well as any other diagnoses (using a general code) that the site considers significant for any reason (due to severity of the illness, impact upon participant’s ART, WHO Stage III-IV or AIDS-defining diagnosis, or for any other reason), since the last visit must be recorded on the CRF, along with any laboratory values and/or signs and symptoms associated with each diagnosis. Sites must refer to the study CRF for the a...
Sample 1
Clinical Assessments 
Sample 1Sample 2Sample 3

Related to Clinical Assessments

  • Risk Assessments a. Risk Assessment - Transfer Agent shall, at least annually, perform risk assessments that are designed to identify material threats (both internal and external) against Fund Data, the likelihood of those threats occurring and the impact of those threats upon the Transfer Agent organization to evaluate and analyze the appropriate level of information security safeguards (“Risk Assessments”).

  • Ergonomic Assessments At the request of the employee, the Employer will ensure that an ergonomic assessment of the employee’s work station is completed by a person trained by the Department of Labor and Industries or comparable trainer to conduct ergonomic assessments. Solutions to identified issues/concerns will be implemented within available resources.

  • Environmental Assessments Foreclose on or take a deed or title to any commercial real estate without first conducting a Phase I environmental assessment of the property or foreclose on any commercial real estate if such environmental assessment indicates the presence of a Hazardous Substance in amounts which, if such foreclosure were to occur, would be material.

  • Diagnostic Assessment 6.3.1 Boards shall provide a list of pre-approved assessment tools consistent with their Board improvement plan for student achievement and which is compliant with Ministry of Education PPM (PPM 155: Diagnostic Assessment in Support of Student Learning, date of issue January 7, 2013).

  • Security Assessments Upon advance written notice by the JBE, Contractor agrees that the JBE shall have reasonable access to Contractor’s operational documentation, records, logs, and databases that relate to data security and the Contractor’s Information Security Program. Upon the JBE’s request, Contractor shall, at its expense, perform, or cause to have performed an assessment of Contractor’s compliance with its privacy and data security obligations. Contractor shall provide to the JBE the results, including any findings and recommendations made by Contractor’s assessors, of such assessment, and, at its expense, take any corrective actions.

  • Loss Assessment We will pay up to $1000 for your share of loss assessment charged during the policy period against you by a corporation or as- sociation of property owners, when the assess- ment is made as a result of:

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Environmental Assessment In connection with its surrender of the Premises, Tenant shall submit to Landlord, at least fifteen (15) days prior to the expiration date of this Lease (or in the event of an earlier termination of this Lease, as soon as reasonably possible following such termination), an environmental Assessment of the Premises by a competent and experienced environmental engineer or engineering firm reasonably satisfactory to Landlord (pursuant to a contract approved by Landlord and providing that Landlord can rely on the Environmental Assessment). If such Environmental Assessment reveals that remediation or Clean-up is required under any Environmental Laws that Tenant is responsible for under this Lease, Tenant shall submit a remediation plan prepared by a recognized environmental consultant and shall be responsible for all costs of remediation and Clean-up, as more particularly provided in Section 5.3, above.

  • Real Estate Taxes and Special Assessments The 2022 calendar year real estate taxes due and payable in 2023 shall be paid by Seller. Seller shall credit Buyer(s) at closing for said 2022 real estate taxes payable in 2023 based on the most recent ascertainable tax figures. Xxxxx is responsible for all subsequent real estate taxes.

  • REAL ESTATE TAXES, SPECIAL ASSESSMENTS AND PRORATIONS (a) Because the Entire Property (of which the Property is a part) is subject to a triple net lease (as further set forth in paragraph 11(a)(i), the parties acknowledge that there shall be no need for a real estate tax proration. However, Seller represents that to the best of its knowledge, all real estate taxes and installments of special assessments due and payable in all years prior to the year of Closing have been paid in full. Unpaid real estate taxes and unpaid levied and pending special assessments existing on the date of Closing shall be the responsibility of Buyer and Seller in proportion to their respective Tenant in Common interests, pro-rated, however, to the date of closing for the period prior to closing, which shall be the responsibility of Seller if Tenant shall not pay the same. Seller and Buyer shall likewise pay all taxes due and payable in the year after Closing and any unpaid installments of special assessments payable therewith and thereafter, if such unpaid levied and pending special assessments and real estate taxes are not paid by any tenant of the Entire Property.

Time is Money Join Law Insider Premium to draft better contracts faster.